The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy

  title={The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy},
  author={James G Carter and Melissa V. R. Gammons and Gopinath Damodaran and Amanda Jane Churchill and Steve Harper and David W Bates},
Anti-VEGF-A therapy has become a mainstay of treatment for ocular neovascularisation and in cancer; however, their effectiveness is not universal, in some cases only benefiting a minority of patients. Anti-VEGF-A therapies bind and block both pro-angiogenic VEGF-Axxx and the partial agonist VEGF-Axxxb isoforms, but their anti-angiogenic benefit only comes about from targeting the pro-angiogenic isoforms. Therefore, antibodies that exclusively target the pro-angiogenic isoforms may be more… CONTINUE READING
5 Extracted Citations
26 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 26 references

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular agerelated macular degeneration: comparison of ranibizumab and bevacizumab

  • P Mitchell
  • Curr Med Res
  • 2011

Effects of exogenous VEGF165b on invasion and migration of human lung adenocarcinoma A549 cells

  • J Chen, Z Li, S Zhang, R Zhang, M Dassarath, G Wu
  • J Huazhong Univ Sci Technol Med Sci
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…